Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7934799 | 0.83 | HTR5A (0.38) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 | |
| SCHEMBL30025550 | 0.79 | ADRA2A (0.34) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 | |
| SCHEMBL7938077 | 0.79 | ADRA2A (0.34) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 | |
| Hydrochloric Acid SCHEMBL11820690 | 0.78 | ADRA2A (0.33) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 | |
| SCHEMBL2145268 | 0.74 | TRPA1 (0.36) | ADRA2AMETAP1PARP10PARP11CYP19A1 | |
| Hydrochloric Acid SCHEMBL14921733 | 0.72 | TRPA1 (0.35) | ADRA2AMETAP1PARP10PARP11CYP19A1 | |
| SCHEMBL21936743 | 0.68 | SLC6A2 (0.35) | HTR5ANOTUM | |
| SCHEMBL12043447 | 0.68 | HTR5A (0.37) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 | |
| SCHEMBL12043446 | 0.68 | HTR5A (0.37) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 | |
| SCHEMBL4724433 | 0.67 | ADRA2A (0.34) | HTR5ACYP1A2CYP2A6ADRA2AMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4234566-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI Shenzhen (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022083686-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2022-04-28 | — | — | WO | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| US-7960411-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2010077589-A2 | STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | HTR5A 4291/4885CYP1A2 4883/4885CYP2A6 4871/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | HTR5A 1367/4885CYP1A2 110/4885CYP2A6 568/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | HTR5A 1813/4885CYP1A2 884/4885CYP2A6 586/4885 |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | HTR5A 151/4885CYP1A2 1726/4885CYP2A6 2265/4885 |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | HTR5A 3032/4885CYP1A2 701/4885CYP2A6 991/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | HTR5A 444/4885CYP1A2 138/4885CYP2A6 207/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | HTR5A 444/4885CYP1A2 138/4885CYP2A6 207/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HTR5A 1787/4885CYP1A2 1024/4885CYP2A6 806/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | HTR5A 64/4885CYP1A2 1924/4885CYP2A6 1059/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | HTR5A 4167/4885CYP1A2 2937/4885CYP2A6 4216/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HTR5A 2063/4885CYP1A2 2270/4885CYP2A6 1646/4885 |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | FLT3, ABL1, MCL1 | HTR5A 3872/4885CYP1A2 3494/4885CYP2A6 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.